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 It is well established that use of nonsteroi-
dal anti-infl ammatory drugs (NSAIDs) 
can result in renal dysfunction, but the 
mechanisms underlying the pathology are 
poorly understood. Th ese compounds act 
by inhibiting cyclooxygenases (COXs), 
the key enzymes in the biosynthesis of 
prostanoids (that is, prostaglandins, 
thromboxanes, and prostacyclins), which 
are key mediators of infl ammation and 
other biological functions. For many 
years, it was assumed that the nephrotoxic 
eff ects of nonselective NSAIDs were due 
to inhibition of COX-1; however, with the 
development of COX-2-selective antago-
nists and COX isoform-specifi c knockout 
mice, it has become evident that the harm-
ful eff ects of NSAIDs are largely achieved 
by their antagonistic action on COX-2. 
For example, a seminal study by Smithies 
and colleagues 1 demonstrated that genetic 
ablation of COX-2 in mice resulted in a 
profound renal phenotype and premature 
death. Over the past decade, many groups 
have contributed to our understanding of 
COX-2 functions in renal physiology. 
Now, a report by K ü per  et al. 2 (this issue) 
provides new insights about the role of 
COX-2 in the adaptation of renal medul-
lary cells to hypertonic stress. 
 COX-2 is present throughout the diff er-
ent regions of the kidney and promotes the 
production of prostaglandins and prosta-
noids. Th e most common action ascribed 
to COX-2 is the conversion of arachidonic 
acid to an intermediate endoperoxide that 
is converted to  prostaglandin E 2 (PGE 2 ), 
PGI 2 , thromboxane A 2 , or PGD 2 through 
the actions of specifi c synthases. Th e bene-
fits or dangers of inhibiting COX-2 
depend on the role of these prostaglandins 
within the kidney. Since K ü per and 
colleagues 2 focus on the role of PGE 2 in 
the renal medullary response to hyper-
tonicity, this Commentary also will be 
limited to the signaling pathways and 
actions of PGE 2 . 
 Cellular responses to PGE 2 are medi-
ated by four subtypes of PGE 2 -specifi c 
receptors, designated EP1 – EP4. 3 EP1 
increases intracellular Ca 2  +   . EP3 interacts 
with the G i heterotrimeric G protein and 
attenuates cyclic adenosine monophos-
phate (cAMP) production. Conversely, 
EP2 and EP4 are coupled to G s , which 
activates adenylyl cyclase, resulting in 
increased production of cAMP. PGE 2 , 
therefore, can infl uence a variety of phys-
iological functions in the kidney. It was 
found to regulate the amounts of Na-K-
ATPase in the inner medulla and Na-
ATPase and organic ion transporters in 
the proximal tubule. PGE 2 and EP4 are 
reportedly involved in podocyte injury 
and impairment of glomerular barrier 
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 Hypertonic stress in the kidney inner medulla is common, yet inner 
medullary cells adapt to limit cell death. K ü per  et al. have identified a 
cell-survival response by which increased cyclooxygenase-2 (COX-2) 
stimulates a prostaglandin E 2 (PGE 2 ) / protein kinase A (PKA)-mediated 
inactivation of the pro-apoptotic protein BAD. However, the PGE 2 / PKA 
pathway is not the only means to inactivate BAD and limit cell death. 
This Commentary shows a broader picture of this pathway to examine 
the kidney ’ s BAD options. 
 Kidney International (2011)  80, 905 – 907;  doi: 10.1038/ki.2011.263 
 1 Renal Division, Department of Medicine, Emory 
University ,  Atlanta ,  Georgia ,  USA  
 Correspondence: Janet D. Klein, Renal Division, 
Emory University School of Medicine, Renal 
Division 1639 Pierce Drive NE, WMB Room 3313B, 
Atlanta, Georgia 30322, USA. 
E-mail:  janet.klein@emory.edu 
Gsα
APOPTOSIS
CELL
SURVIVAL
P
P
BAD
(active)
–BAD
(inactive)
PKA
Hypertonicity
Arachidonic acid COOH
COX-2
PGH2
PGE2
PGES
EP2
receptor
cAMP
 Figure 1  |  Hypertonic stress signaling via prostaglandin E 2 . The diagram depicts the signaling 
pathway proposed by K ü per  et al. 2 for prostaglandin E 2 (PGE 2 )-mediated inactivation of the 
pro-apoptotic protein BAD. Hypertonicity increases cyclooxygenase-2 (COX-2) activity, which 
catalyzes the production of unstable prostaglandin H 2 (PGH 2 ) from arachidonic acid. PGH 2 
is rapidly converted to PGE 2 by prostaglandin E synthase (PGES). PGE 2 binds to its receptor 
EP2, which is coupled to G s α  . G s α  activates adenylyl cyclase, which produces cyclic adenosine 
monophosphate (cAMP), leading to activation of protein kinase A (PKA). PKA then phosphorylates 
and inactivates BAD. 
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function. PGE 2 with EP2 or EP4 has been 
directly implicated in the release of renin 
from the macula densa and a variety of 
vasodilatory effects throughout the 
kidney. Conversely, PGE 2 and EP1 have 
been shown to induce vasoconstriction. 
Apart from transport, fi ltration, and vas-
cular effects, PGE 2 also can modulate 
anti-fibrosis and epithelial-cell injury 
responses. PGE 2 in the kidney, therefore, 
exerts eff ects that span from protective to 
deleterious depending largely on the 
receptor subtype that is activated but also 
on other inputs such as hormone signals, 
substrate availability, or duration of expo-
sure. Excellent reviews are available for an 
introduction to the literature on prosta-
glandins in the kidney. 3,4 
 Over the past decade, the renoprotec-
tive functions of prostaglandins in the 
kidney have become evident, but our 
understanding of the responsible mecha-
nism has been slower to emerge. Neuhofer 
and colleagues have contributed signifi -
cantly to this area by examining the role 
of PGE 2 in the responses of renal medul-
lary cells to hypertonic stress such as 
occurs during dehydration or antidiuresis. 
Even though the collecting duct is always 
hypertonic relative to serum, dehydration 
can increase the interstitial osmolality 
severalfold to levels that, if prolonged, lead 
to cellular distress and death by apoptosis 
unless intercellular adaptations that enable 
survival occur (reviewed by Burg  et al. 5 ). 
Steinert  et al. 6 demonstrated that one such 
adaptive response to hyperosmolality in 
renal medullary cells is the induction of 
COX-2 through a feedback loop signaling 
pathway involving the EP2 receptor and a 
cAMP / PKA / CREB response. Interest-
ingly, they also found that hyperosmolar 
conditions cause the activation of protein 
kinase A (PKA), which, in turn, phospho-
rylates serine (Ser)-155 in the pro-
 apoptotic protein BAD ( Figure 1 ). Th is 
observation was the fi rst hint about how 
COX-2 protects inner medullary cells 
from apoptosis. Pro-apoptotic BAD binds 
to anti-apoptotic members of the Bcl-2 
protein family, such as Bcl-xL. When 
active, these anti-apoptotic proteins pre-
vent the release of cytochrome  c from 
mitochondria, disabling the formation of 
an apoptosome complex that otherwise 
would activate the caspase cascade, 
 leading to cell death. Phosphorylation of 
BAD prohibits the association with the 
Bcl-2 family members, thus allowing their 
anti-apoptotic function and promoting 
cell survival. 
 In their latest work, K ü per  et al. 2 used 
mice and cells with genetically manipu-
lated levels of COX-2 to provide impor-
tant pieces of this puzzle. In response to 
hypertonic conditions induced by water 
deprivation, COX-2   −  /  −   mice had lower 
PGE 2 , less phosphorylated BAD, and 
greater apoptosis of renal tubular epithe-
lial cells compared with COX-2   +  /  +   mice. 
Th e group then used RNA interference 
technology to knock down the level of 
BAD in MDCK cells and demonstrate 
that BAD phosphorylation was key for 
the PGE 2 -mediated attenuation of cas-
pase-3 activity in cells incubated in 
hypertonic media. As in the earlier stud-
ies, BAD phosphorylation and caspase-3 
activity in hypertonically stressed cells 
were sensitive to inhibition of PKA and 
EP2. From these elegant studies, it is clear 
that induction of COX-2 in response to 
osmotic stress is a critical adaptation 
that activates cAMP-mediated anti-apop-
totic mechanisms that allow renal tubular 
cells to survive in harsh extracellular 
environments. Details of the relevant 
signaling and apo ptotic pathways are 
shown in  Figure 1 . 
 It should be noted that BAD serves as a 
nexus for a variety of signaling pathways, 
including those activated by growth 
factors (for example, epidermal growth 
factor-1), hormones (for example, angio-
tensin II), and other physiological media-
tors. Th ese pathways phosphorylate BAD 
on Ser-112, Ser-136, and Ser-155 
(reviewed by Danial 7 ). K ü per and col-
leagues focused on Ser-155 of BAD, which 
is modifi ed by PKA. 2 In an earlier study 
(Steinert  et al. 6 ), their group reported that 
inhibition of PKA prevented only par-
tially the PGE 2 -induced phosphorylation 
of BAD. Th is suggests that other signaling 
mediators may be activated by hyperton-
icity and be involved in BAD-mediated 
apoptosis. For example, cAMP activates 
exchange  protein directly activated 
by cAMP (EPAC) as well as PKA, and 
EPAC activates the MEK / ERK / RSK 
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 Figure 2  |  BAD signaling. This diagram shows possible alternative regulatory pathways that result 
in phosphorylation and inactivation of BAD, resulting in enhanced cell survival. Prostaglandin 
E 2 (PGE 2 ) initiates an increase in cAMP that can activate protein kinase A (PKA) and EPAC, both 
of which can phosphorylate BAD on Ser-155 by different signaling pathways. RSK, which is 
downstream of EPAC, can also be activated by protein kinase C (PKC) independently of cAMP. 
Other signaling pathways can influence BAD activity by phosphorylating serine residues other 
than Ser-155 (e.g., Ser-112, Ser-136). For example, AKT can be activated by phosphatidylinositol-
3-kinase (PI3K) and heat-shock proteins 90 (HSP90) and 27 (HSP27). AKT phosphorylates BAD on 
Ser-136, which promotes inactivation by cytosolic sequestration. BAD binds to and inactivates 
anti-apoptotic proteins at the mitochondria, resulting in release of cytochrome  c and activation of 
the caspase cascade, leading to cell death. Phosphorylation of BAD prevents this binding and thus 
leads to cell survival. 
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signaling system. Th is is notable because 
RSK also phosphorylates BAD on Ser-155 
 ( Figure 2 ). PGE 2 , acting through EP2/
EP4, has been shown to activate Rap1 
through an EPAC signaling pathway; 8 
Rap1 is upstream of MEK / ERK / RSK. In 
unrelated studies, Wang  et al. 9 found that 
EPAC acts coordinately with PKA in renal 
inner medullary collecting duct cells to 
alter urea movement and potentially other 
transport processes that are important for 
renal-cell osmoregulation. While the 
study did not examine the potential 
involvement of PGE 2 , it demonstrated 
that hypertonicity activates the EPAC 
pathway in the inner medulla. When con-
sidered altogether, these studies suggest 
that PGE 2 can modulate BAD activity and 
apoptosis in the renal tubular epithelial 
cells in the inner medulla by activating 
parallel signaling pathways involving 
EPAC and PKA. 
 Although the hypertonicity-induced 
increase in COX-2 activity can antagonize 
the apoptotic action of BAD, the potential 
negative eff ects of COX-2 should not be 
ignored. In situations where increased 
PGE 2 would be detrimental, there are alter-
nate means by which BAD can be phos-
phorylated that off er an alternate control 
of apoptosis for the kidney. 7 Ser-155 can 
be phosphorylated by RSK following acti-
vation of protein kinase C ( Figure 2 ). Phos-
phatidylinositol-3-kinase (PI3K) and 
heat-shock proteins HSP90 and HSP27 
stimulate AKT to inactivate BAD by phos-
phory lating it on Ser-136. 
 In conclusion, the work of K ü per  et al. 2 
provides new insights into the mecha-
nisms responsible for the deleterious 
eff ects of reducing COX-2 activity phar-
macologically or genetically in the kidney, 
by characterizing the key roles of PGE 2 
and BAD in the survival responses of renal 
epithelial cells to hypertonic stress. Th e 
study suggests that inhibition of COX-2 
by NSAIDs could be detrimental to inner 
medullary epithelial cells by increasing 
the pro-apoptotic actions of BAD and 
ultimately cell death. Given the complex-
ity of responses that can be evoked 
by COX-2-generated prostaglandins, 
and the potential for non-prostaglandin-
mediated regulation of BAD function, 
caution should be exercised not to over-
simplify the control of apoptosis in the 
renal medulla and the role of NSAIDs 
in this process. 
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 A new regulator of the vacuolar 
H   +   -ATPase in the kidney 
 Dominique  Eladari 1 , 2 , 3 and  Jacques  Teulon 1   
 Xu  et al. identify Slc26a11, a novel member of the Slc26 anion exchanger 
family, as an electrogenic (Cl   −   ) n / HCO 3 
  −   exchanger. Functional 
characterization of this transporter suggests that Slc26a11 mediates 
classical electroneutral Cl   −   / HCO 3 
  −   exchange but also exhibits an 
electrogenic Cl   −   conductance. In the kidney, Slc26a11 colocalizes with 
the vacuolar H   +   -ATPase in intercalated cells, emphasizing the 
cooperation of the proton pump with chloride transporters. 
 Kidney International (2011)  80, 907 – 909;  doi: 10.1038/ki.2011.220 
 Vacuolar H   +   -ATPases (V-ATPases) are 
large multiprotein complexes that use the 
energy produced by adenosine triphos-
phate (ATP) breakdown to pump protons 
across cell membranes. In eukaryotic 
cells, the V-ATPases are expressed ubiq-
uitously in intracellular organelles, where 
they play a critical role in their acidifi ca-
tion and intracellular traffi  cking. Th ey are 
also present at the plasma membrane of 
some specialized cells, such as osteoclasts 
and kidney epithelial cells, where they 
mediate acidifi cation of the extracellular 
space or are involved in acid – base trans-
port. A large set of published data indi-
cates that Cl   −   channels or transporters 
might infl uence the activity of V-ATPases, 
via several possible mechanisms. 
 In this issue, Xu  et al. 1 identify Slc26a11, 
a member of the Slc26 exchanger super-
family, as a novel partner of the V-ATPase 
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